Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp)

The summary for the Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp): The National Cancer Institute (NCI) administers two unique programs focused on supporting technology development research that offer transformative potential for advancing cancer research. The Innovative Molecular Analysis Technologies (IMAT) program supports highly innovative, data-generating platforms and methodologies while the Informatics Technologies for Cancer Research (ITCR) program supports powerful data processing and visualization technologies.

Federal Grant Title:	Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-17-143
Type of Funding:	Grant
CFDA Numbers:	93.394
CFDA Descriptions:	Information not provided
Current Application Deadline:	December 12th, 2017
Original Application Deadline:	December 12th, 2017
Posted Date:	January 27th, 2017
Creation Date:	January 27th, 2017
Archive Date:	January 12th, 2018
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	20
Cost Sharing or Matching:	No
Last Updated:	January 27th, 2017

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations); Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See Funding Opportunity for Eligibility Details
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PA-17-143.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologi...; • Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...; • Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate C...; • Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic...; • Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...; • Image-Guided Cancer Interventions (STTR [R41/R42]); • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44); • In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...